Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors

Pfizer

Status and phase: Completed; Phase 2; Phase 1

Conditions: Ewing's Sarcoma Family of Tumors

Treatments: Drug: CP-751,871

Study type: Interventional

Funder types: Industry

Identifiers

NCT00560235

A4021020

Details and patient eligibility

About

Define the efficacy of CP-751,871 in patients with Ewing's sarcoma family of tumors

Enrollment: 138 patients

Sex: All

Ages: 10+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ewing's family of tumors
• Current disease state for which there is no curative therapy

Exclusion criteria

• Prior anti-IGF-1R therapy
• Concurrent treatment with other anti-cancer agents

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

138 participants in 1 patient group

1

Experimental group

Treatment:

Drug: CP-751,871